Beam Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Beam Therapeutics (BEAM).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

15Buy

3Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$48Upside to Avg. PT+69.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$65→$28
Oct 15, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
Oct 14, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$65
Sep 9, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$65
Aug 25, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
Jul 8, 2026	B of A Securities	Alec Stranahan	Maintained	Buy	$47
Jul 7, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
May 13, 2026	Bernstein	William Pickering	PT Cut	Outperform	$40→$39
Mar 26, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$64→$68
Feb 25, 2026	RBC Capital	Luca Issi	PT Raise	Sector Perform	$22→$26
Feb 25, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$57→$65
Feb 20, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$74
Jan 21, 2026	Bernstein	William Pickering	PT Raise	Outperform	$37→$41
Jan 7, 2026	UBS	Michael Yee	Initiate	Neutral	$28
Nov 24, 2025	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$35
Oct 10, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
Oct 9, 2025	JP Morgan	Eric Joseph	PT Cut	Overweight	$48→$46
Sep 15, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$80
Aug 6, 2025	Barclays	Gena Wang	PT Cut	Equal-Weight	$25→$21
May 7, 2025	Guggenheim	Debjit Chattopadhyay	PT Cut	Buy	$78→$55

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28

Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $65 to $28.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.

Benzinga Newsdesk

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

B of A Securities analyst Alec Stranahan reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $47 price target.

Benzinga Newsdesk

Beam Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Beam Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

People Also Watch

People Also Watch

Beam Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Beam Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28

PROHC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PROWedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PROWedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PROHC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PROB of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target

People Also Watch

People Also Watch

PRO
Wedbush Maintains Outperform on Beam Therapeutics, Lowers Price Target to $28

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

PRO
B of A Securities Reiterates Buy on Beam Therapeutics, Maintains $47 Price Target